Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
XORTX Therapeutics Inc ( (TSE:XRTX) ) has issued an announcement.
On June 26, 2025, XORTX Therapeutics Inc. announced a non-brokered private placement to raise up to USD $925,000 through issuing common share units. This strategic move aims to fund the company’s programs for gout and support general corporate purposes. The offering will be available to Canadian residents, excluding Quebec, and other qualifying jurisdictions, with securities not subject to a hold period under Canadian laws. The closing date is expected around July 4, 2025, pending necessary approvals. This initiative is likely to bolster XORTX’s financial position, aiding its efforts to advance its clinical programs and strengthen its market presence in the pharmaceutical industry.
The most recent analyst rating on (TSE:XRTX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Underperform.
XORTX Therapeutics Inc faces significant challenges with no revenue and consistent losses, leading to a low financial performance score. Technical analysis indicates a neutral to bearish outlook, which, along with poor valuation metrics, weighs down the overall stock score. However, potential advancements in FDA discussions for gout treatment provide a glimmer of hope for future revenue generation, but current financial and compliance risks remain substantial.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for treating gout and progressive kidney disease. The company is advancing three clinically advanced products, including XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute organ injury related to respiratory virus infections, as well as a pre-clinical program for Type 2 diabetic nephropathy. XORTX aims to target aberrant purine metabolism and xanthine oxidase to reduce uric acid production, ultimately improving the quality of life for individuals with these conditions.
Average Trading Volume: 3,586
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.17M
Find detailed analytics on XRTX stock on TipRanks’ Stock Analysis page.